Nucleus Network commences first COVID-19 vaccine trial in Australia

Nucleus Network has begun the Phase 1/2 COVID-19 vaccine trial in Australia on behalf of Novavax, Inc., the developer of NVX-CoV2373 and sponsor of the trial, with funding support from the Norway-based Coalition for Epidemic Preparedness Innovations (CEPI), joining the global response to this pandemic.

Victorian Parliamentary Secretary for Medical Research, The Hon. Frank McGuire, formally launched the Novavax trial with Nucleus Network in Melbourne today, saying this was a significant step forward in the race for a vaccine.

Vaccines are one of mankind’s greatest achievements in saving lives and livelihoods.

The Hon. Frank McGuire

Nucleus Network Melbourne initiated the Phase 1 portion of the Phase 1/2 trial on 26 May 2020 with additional dosing at its Brisbane clinic. Approximately 130 healthy participants, aged 18 to 59 years of age, in Melbourne and Brisbane have been screened to take part in this portion of the Novavax trial. The trial will be under the guidance of leading medical experts in clinical trials including Nucleus Network Chief Medical Officer, Dr. Jason Lickliter, and Nucleus Network Infectious Diseases Physician and Microbiologist Dr. Paul Griffin.